Arcus Biosciences, Inc.
RCUS · NYSE
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Market Cap | $1,448,400 | $863,654 | $772,440 | $1,365,413 |
| - Cash | $238,000 | $248,000 | $192,000 | $150,000 |
| + Debt | $98,000 | $109,000 | $60,000 | $60,000 |
| Enterprise Value | $1,308,400 | $724,654 | $640,440 | $1,275,413 |
| Revenue | $26,000 | $160,000 | $28,000 | $26,000 |
| % Growth | -83.8% | 471.4% | 7.7% | – |
| Gross Profit | $24,000 | $160,000 | $28,000 | $26,000 |
| % Margin | 92.3% | 100% | 100% | 100% |
| EBITDA | -$130,000 | $4,000 | -$108,000 | -$89,000 |
| % Margin | -500% | 2.5% | -385.7% | -342.3% |
| Net Income | -$135,000 | -$8,000 | -$112,000 | -$94,000 |
| % Margin | -519.2% | -5% | -400% | -361.5% |
| EPS Diluted | -1.27 | 0.043 | -1.14 | -1.03 |
| % Growth | -3,026.3% | 103.8% | -10.7% | – |
| Operating Cash Flow | -$97,000 | -$133,000 | -$132,000 | -$100,000 |
| Capital Expenditures | $0 | $0 | -$1,000 | -$1,000 |
| Free Cash Flow | -$97,000 | -$133,000 | -$133,000 | -$101,000 |